Bravo Bruna S F, Bravo Leonardo G, Gouvea Bárbara F, Neves Marina R B, Nobre Camila S, Silva Camila D S, do Nascimento Carolina Machado Ozório Lopes
Department of Dermatology, Bravo Private Clinic, Rio de Janeiro 22440-032, Brazil.
Innovapharma Brasil Farmaceutica Ltda, São Paulo 04578-910, Brazil.
J Clin Med. 2025 Jun 9;14(12):4072. doi: 10.3390/jcm14124072.
: Calcium hydroxylapatite (CaHA)-based dermal fillers are widely used in esthetic medicine due to their dual volumizing and biostimulatory properties. Despite their rising popularity, comparative clinical outcome data evaluating different CaHA fillers remain limited. This prospective, single-center, unblinded study aimed to establish the effectiveness of the CaHA filler Rennova Diamond Intense via comparison to the well-established CaHA filler Radiesse in terms of clinical performance, safety, and patient satisfaction. : Thirty patients (28 female, 2 male) underwent a single-session bilateral injection of Rennova Diamond Intense (right side) and Radiesse (left side) in the lower and medial posterior facial regions. Outcomes evaluated at multiple time points included dermal thickness, skin elasticity, transepidermal water loss, patient-reported outcomes (S-GAIS), physician-assessed outcomes (P-GAIS), and adverse events. : Both fillers showed improvements across all parameters. Patient-reported S-GAIS indicated predominantly "improved" outcomes at days 60 and 120, whereas physician assessments (P-GAIS) predominantly indicated "very improved" results at day 120. Ultrasound revealed increases in dermal thickness for both fillers. Similarly, improvements in skin elasticity and decreases in transepidermal water loss were observed bilaterally. Mild, transient adverse events (pain, swelling, redness, bruising) resolved spontaneously within 30 days post injection. : Rennova Diamond Intense effectively increases dermal thickness, improves skin elasticity, and reduces transepidermal water loss, achieving high patient and physician satisfaction. These findings underscore its safety, versatility, and efficacy for esthetic facial rejuvenation, warranting further long-term evaluation.
基于羟基磷灰石钙（CaHA）的真皮填充剂因其兼具填充和生物刺激双重特性而在美容医学中被广泛应用。尽管其越来越受欢迎，但评估不同CaHA填充剂的比较临床结果数据仍然有限。这项前瞻性、单中心、非盲研究旨在通过与成熟的CaHA填充剂瑞得喜（Radiesse）在临床表现、安全性和患者满意度方面进行比较，来确定CaHA填充剂瑞诺瓦钻石极致版（Rennova Diamond Intense）的有效性。30名患者（28名女性，2名男性）在面部中下部和后部区域接受了单次双侧注射，右侧注射瑞诺瓦钻石极致版，左侧注射瑞得喜。在多个时间点评估的结果包括真皮厚度、皮肤弹性、经表皮水分流失、患者报告结果（S-GAIS）、医生评估结果（P-GAIS）和不良事件。两种填充剂在所有参数上均显示出改善。患者报告的S-GAIS显示在第60天和120天时主要为“改善”结果，而医生评估（P-GAIS）在第120天时主要显示为“非常改善”结果。超声显示两种填充剂的真皮厚度均增加。同样，双侧均观察到皮肤弹性改善和经表皮水分流失减少。轻度、短暂的不良事件（疼痛、肿胀、发红、瘀伤）在注射后30天内自发消退。瑞诺瓦钻石极致版有效地增加了真皮厚度，改善了皮肤弹性，并减少了经表皮水分流失，获得了患者和医生的高度满意度。这些发现强调了其在面部美容年轻化方面的安全性、多功能性和有效性，值得进一步进行长期评估。
